A b s t r a c t
Atypical adenomatous hyperplasia (AAH) is a recently introduced preinvasive lesion in the 2004 World Health
Organization (WHO) lung tumor classification as a possible precursor of adenocarcinoma. 1 AAH is a focal, slightly atypical proliferation of monolayer cuboidal pneumocytes with distinct margins, measuring less than 5 mm in maximum diameter, and appears as a solitary or multifocal small ground-glass nodule in a high-resolution computed tomography scan. [1] [2] [3] [4] [5] [6] Some authors subdivide AAH into low and high grade, but this issue remains controversial, and subdivision is not recommended by the 2004 WHO classification. The differential diagnosis between AAH and nonmucinous-type bronchioloalveolar carcinoma (nmBAC) may be difficult, and distinction is basically related to the size of the lesion and the cytologic characteristics of the cells. [1] [2] [3] [4] Although AAH foci are mainly found in patients with multiple synchronous lung adenocarcinomas, it is hard to prove that the former is a precursor of the latter. Previous studies have highlighted the presence of several genetic alterations in AAH and then demonstrated the neoplastic nature of this lesion. [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) deeply involved in the carcinogenesis of non-small cell lung cancer (NSCLC), mainly adenocarcinomas. 24 A subset of patients with NSCLC experienced a significant improvement of symptoms and/or survival using orally dispensed small molecules acting as EGFR selective inhibitors (ie, erlotinib and gefitinib). [25] [26] [27] In addition, up to 20% of unselected patients with chemorefractory NSCLC had a partial to complete regression of the mass using EGFR inhibitors. 28 Female sex, a history of never smoking, Asian ethnicity, and a histologic finding of adenocarcinoma with bronchioloalveolar features are the most important clinicopathologic parameters for predicting tumor response to EGFR RTK inhibitors. [25] [26] [27] [29] [30] [31] [32] Among the biologic predictive markers studied until now, EGFR somatic mutations occurring at exons 19 and 21 (encoding for the EGFR RTK domain) represent the most promising predictive factor for drug efficacy with dramatic clinical responses, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] whereas the finding of a K-ras mutation (mainly involving codons 12 and 13 at exon 2) is the single most important parameter for foreseeing primary resistance to tumor drugs. [46] [47] [48] [49] In addition, several studies have found HER2 mutations in a small (about 2%) subset of patients with adenocarcinoma showing the same clinicopathologic characteristics of EGFR-mutated tumors, also pointing out that EGFR, HER2, and K-ras mutations are mutually exclusive. [50] [51] [52] Mutations involving all of these genes are thought to represent early events in the carcinogenesis of lung adenocarcinoma in never (EGFR and HER2) and current smokers (K-ras).
In this study, we analyzed EGFR, HER2, and K-ras mutational events in 18 cases of adenocarcinoma and concomitant AAH from 13 patients to compare their genetic alterations and to evaluate their possible role as an early molecular step, which may support the AAH-pulmonary adenocarcinoma sequence.
Materials and Methods
We obtained 18 cases of primary lung adenocarcinoma, associated with foci of AAH obtained from 13 patients, from the files of the Section of Pathologic Anatomy, Hospital Policlinico, Modena, Italy, from January 2003 to March 2007. Case series included 3 patients with multiple tumors (1 patient with 4 distinct tumors in 3 different lobes, 1 with 2 tumors in the same lobe and 1 with 2 tumors in different lobes). All available slides were reviewed at a multiheaded microscope by 3 pathologists (A.C., M.C., and G.R.) according to the criteria set by the WHO lung tumors classification. 1 All cases of AAH consisted of incidental findings observed in pulmonary resections for primary lung cancer.
All cases consisted of a surgical specimen (10 lobectomies, 6 wedge resections, and 1 pneumonectomy) that was routinely fixed in 10% buffered formalin. Only cases in which foci of AAH were present in at least 5 consecutive 5-µm serial sections were included in the study to obtain sufficient cells for DNA isolation. After gross examination, the sampled tissues were embedded in paraffin blocks. A mean of 12 H&E-stained slides (range, 6-22 slides) per case were available.
Patients were subdivided into never smokers, former smokers (stopped smoking at least 3 years before diagnosis), and current smokers. Clinical data were obtained from pathologic reports, clinical charts, referring physicians, or the patients' families. The study did not require approval by the local ethics committee or institutional review board because the samples were coded and the names of patients not revealed.
Mutational Analysis
For the study, 5-µm thick sections obtained from a representative paraffin-embedded block were deparaffinized by xylene, and tumor DNA was extracted by using a manual microdissection method under a microscope (Nikon E600, Tokyo, Japan). Microdissected tumor cells were subjected to Proteinase K treatment in a digestion buffer (50 mmol/L of tris(hydroxymethyl)aminomethane [pH 8.5], 1 mmol/L of EDTA, and 0.5% polysorbate 20) and then incubated overnight at 37°C.
Polymerase chain reaction (PCR) was performed in 20-µL reactions containing 2.0 µL of DNA, 2 µL of commercial PCR buffer (Applied Biosystems, Foster City, CA), 1.0 to -1.5 mmol/L of magnesium chloride, 200 µmol/L of each deoxynucleoside triphosphate, 20 pmol of each primer, and 3 U of AmpliTaq gold polymerase (Applied Biosystems). The PCR reaction was carried out on a Uno II Thermoblock (Biometra, Gottingen, Germany). Initial denaturation at 94°C for 10 minutes was followed by 41 cycles and a final extension step (7 minutes at 72°C). The cycles included denaturation at 95°C for 1 minute, annealing at 55°C to 58°C for 1 minute, and extension at 72°C for 2 minutes. The amplified DNA was electrophoresed on 2% agarose gel for 1 hour at 110 V. The amplification products were then purified by using the MinElute PCR Purification Kit (Qiagen, Hilden, Germany) as indicated by the manufacturer's instructions. PCR products were then sequenced in both directions with the ABI Prism BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems), using the same primers as used for PCR. PCR products were finally purified by Centri-Sep Spin Columns (Applied Biosystems) and subsequently run on the ABI Prism 310 automatic sequencer (Applied Biosystems). The data were analyzed with Sequencing Analysis 5. 
Results
The clinicopathologic characteristics of the cases are summarized in ❚Table 2❚. There were 18 cases of adenocarcinoma and AAH-related foci from 13 patients, 8 women and 5 men with a mean age of 59.6 years (range, 43-73 years). Seven patients were current smokers, 3 had no history of smoking, and 3 were former smokers. Three patients (all women) had multiple tumors (cases 2, 3, and 7). By the end of the study, 8 patients were well without disease, 4 were alive with disease, and 1 died of disease. The mean follow-up was 24.9 months (range, 2-74 months). Among adenocarcinomas, there were 10 classic acinar type, 3 nm-BAC, 2 mixed acinar-mucinous BAC, 2 papillary type, and 1 mucinous BAC. Results of mutational status studies for EGFR, HER2, and K-ras are listed in ❚Table 3❚.
Four cases of adenocarcinoma (22%; 3 nm-BAC and 1 acinar type) harbored EGFR mutations, and all consisted of puntiform mutations in exon 21 (L858R) ❚Image 1A❚, ❚Image 1B❚, ❚Image 1C❚, and ❚Image 1D❚. Three of these cases had an identical mutation in AAH-related foci, whereas in the remaining case, AAH-related foci were of the wild type. All of these EGFR mutations occurred in women who were never (3 cases) or former smokers. Mutations of the K-ras gene were observed in 4 cases. Three cases had mutations at codon 12 (G12C, G12D, G12S) and 1 at codon 13. Half of these cases had an identical mutation also in AAH-related lesions ❚Image 1E❚, ❚Image 1F❚, ❚Image 1G❚, and ❚Image 1H❚, while 2 cases of concomitant AAH were of the wild type. Mutations of K-ras were found in 2 current, 1 former, and 1 never smoker (3 women and 1 man). Two patients had papillary type adenocarcinoma, 1 had mucinous BAC, and 1 had mixed acinar-mucinous BAC. None of the tumors with EGFR mutations had K-ras mutations, and no mutations of HER2 were observed in adenocarcinomas or AAH. Among adenocarcinoma and related AAH, concordant mutations of EGFR (3 of 4) or K-ras (2 of 4) were observed in 5 (63%) of 8 cases.
Multiple tumors were metachronous in 2 cases (cases 2 and 7) and synchronous in 1 (case 3). Of note, none of those cases had an identical mutational setup. In multiple tumors, all EGFR mutations occurred in nm-BAC, whereas K-ras mutations were found in 1 papillary adenocarcinoma and in 1 mucinous BAC.
Overall, concordant mutational findings between adenocarcinoma and AAH-related foci were observed in 15 cases (83%; 5 cases with EGFR or K-ras mutations and 10 with wild-type genome), whereas 3 cases had discordant mutations of EGFR (1 case) or K-ras (2 cases).
Discussion
AAH was first described in detail by Shimosato et al 53 and Kodama et al 54 as a lesion frequently occurring in lung resections for adenocarcinomas. Basically, this association and the close morphologic resemblance with nmBAC remain the most important evidence supporting the adenoma-carcinoma sequence in the multistep tumor pathway of lung adenocarcinoma. [1] [2] [3] [4] [5] [55] [56] [57] [58] [59] [60] [61] Several genetic studies have confirmed the neoplastic nature of AAH. In particular, the finding of loss of heterozygosity at the 3p, 9p, and 17p loci 13, [16] [17] [18] and the K-ras mutations in 155 to 50% of such lesions 8, 14, 62, 63 seem to convincingly support the close genetic relationship between adenocarcinoma and concomitant AAH foci.
More recently, Morandi et al 23 showed the lack of a clonal relationship between AAH and associated tumors in 9 of 13 informative cases analyzed by direct sequencing of mitochondrial DNA. However, a close genetic correlation was instead found in a small subset of adenocarcinomas and AAH-related lesions. 23 Based on previous work, 23, 64 identical genetic alterations between adenocarcinoma and AAH may suggest the precursor role of AAH in adenocarcinomagenesis but alternatively may represent a spread of tumor cells from the adenocarcinoma, mainly when AAH is of high grade. The finding in our study of mutations in adenocarcinoma or adenocarcinoma and concomitant AAH, but not in AAH alone, seems to favor the role of AAH as a precursor of adenocarcinoma (through the adenoma-carcinoma progression) rather than the result of tumor cells spreading (through the carcinoma-adenoma sequence).
The recent discovery of EGFR mutations in lung tumors sensitive to small molecule tyrosine kinase inhibitors (TKI) targeting EGFR (ie, gefitinib and erlotinib) has generated great interest in lung carcinogenesis. EGFR mutations are, in fact, more frequent in female nonsmokers with histologic findings of adenocarcinoma and possibly of Asian ethnicity. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] 250 1,300 1,350 1,400 1,450 1,500 1,550 1,600 1,650 1,700 1,750 1 ,800   115  120  125  130  135  140  145  150   C C C C CC  C  C  C CC  C  CM  A  A  A  AA A A  G  G  G  G G  G  GG  T TT  T TT  T  A  G A A  T  T  C  C  T T  T In addition, occurrence of EGFR and K-ras mutations in lung cancer seems to be mutually exclusive, K-ras mutations being more frequently observed in smokers and representing a sign of primary resistance to TKI. [46] [47] [48] [49] 65, 66 Mutational events involving HER2/neu have been observed in a minor subset of NSCLCs in patients with the same clinicopathologic characteristics as patients with EGFR mutations. HER2 mutations were mutually exclusive with EGFR and K-ras. 51, 52 When altered, all of these genes are thought to be involved in the early stage of pathogenesis of pulmonary adenocarcinoma, but only a few studies have investigated mutations of EGFR, HER2, and K-ras in adenocarcinoma and related AAH, and they have controversial results. [67] [68] [69] Yatabe et al 67 found EGFR mutations in 2 of 7 AAH cases, 1 of which was identical to the concomitant adenocarcinoma. By contrast, Haneda et al 68 found no EGFR mutations in the 5 tested AAH lesions, and Yoshida et al 69 found EGFR mutations in 1 (3%) of 35 AAH lesions and K-ras mutations in 8 (27%) of 30 AAH lesions among patients with multiple lung tumors. However, identical mutations of neither EGFR nor K-ras were observed in AAH and related tumors. 69 In this study, we analyzed 18 cases of AAH and concomitant adenocarcinoma (obtained from 13 patients) for EGFR, HER2, and K-ras mutations. A mutational event was found in 8 cases (44%), 4 cases each involving EGFR and K-ras, whereas HER2 was of the wild type in all cases. Mutations were mutually exclusive. An identical EGFR mutation on B exon 21 (L858R) among AAH and concomitant adenocarcinoma was observed in 3 of 4 cases; all of these patients were women with nmBAC (2 never and 1 former smoker). Four adenocarcinomas had K-ras mutations on exon 2 (3 at codon 12 and 1 at codon 13), 2 of which showed an identical mutation with the concurrent AAH. Mutations occurring only in AAH were not observed.
Our results support the data by Yatabe et al, 67 suggesting the early role of EGFR in the pathogenesis of a subset of lung adenocarcinomas possibly originating from the terminal respiratory unit because all EGFR-mutated AAH lesions were associated with nmBAC, the prototype of such peripheral type of adenocarcinoma. Although our case series is too limited to make conclusive remarks, the finding of all EGFR mutations characterized by the leucine to arginine substitution at codon 858 (L858R) on exon 21 and mainly involving nmBAC is in agreement with a previous study on 860 NSCLCs by Marchetti et al. 65 In this large study of Italian patients, the authors found that the L858R EGFR mutation was the most frequently observed and more than two thirds of EGFR mutations were of the nmBAC histologic type.
The finding of an identical K-ras mutation in 2 of 4 adenocarcinoma and AAH lesions (both women, 1 never smoker and 1 current smoker) further suggest the role of K-ras as another gene altered early in lung adenocarcinoma, not only in current smokers, but also in a minority of never smokers. [70] [71] [72] Interestingly, Kim et al 73 recently underscored the significant relationship between the papillary subtype of adenocarcinoma and the response to gefitinib. However, we identified Kras mutations, a biologic predictor of resistance to TKI, in both E   C  C  C  C  C   35  40  45  50  55  60  65  70  75   400  450  500  550  600  650  700  750  800  850   A  A AA  A  A  A  A A  A W  G  G G G  G  G G G  GG G G G  G  G G  T  T  T T T  T  T T  T  T  T   F   G   C  C  C  C  C   40  45  50  55  60  65  70  75   450  500  550  600  650  700  750  800  850  900 cases of papillary adenocarcinoma present in our series (1 man, a current smoker, and 1 woman, a never smoker). The papillary variant of adenocarcinoma may result in a challenging and poorly reproducible diagnosis. The true papillary variant of adenocarcinoma is uncommon and originally was associated with men who were current smokers and with a poor prognosis. 74, 75 But papillary structures are frequently found in nmBAC, with which there is striking morphologic overlap, 76, 77 and more recent studies on papillary adenocarcinoma found a close relationship with nonsmoking women. 78 Of note, all of these features (nmBAC, female sex, and nonsmoking history) are significantly related to EGFR mutations and responsiveness to TKI. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] One patient (case 7) had 4 lung adenocarcinomas during a period of 6 years. All the tumors were associated with AAH in the adjacent normal pulmonary parenchyma, and an identical mutation involving EGFR and K-ras was observed in AAH and adenocarcinoma in 2 of 4 lesions. Similarly, case 3 experienced the occurrence of 2 lung tumors with various mutational setups for EGFR and K-ras, and case 2 had an EGFR-mutated nmBAC and a wild-type acinar adenocarcinoma. In both tumors in case 2, the AAH mutational setup was concordant with that of the adenocarcinoma. These findings further highlight the genetic heterogeneity of multiple lung tumors occurring in the same patient. 79 In addition, one of these patients (case 7) was the only one undergoing treatment with EGFR TKI (erlotinib), but without clinical response. The patient started erlotinib treatment after the third tumor occurrence when molecular analysis showed a K-ras mutation in the lung tumor. Because patients with adenocarcinoma tend to have multiple tumors at a significant rate, 1,4,5,57 the finding of different mutations in multiple tumors ("field effect" cancerization) underscores the importance of testing the biologic characteristics of each synchronous or metachronous multiple lung tumor in order to provide molecular therapies when the neoplasm is more sensitive to EGFR TKI. 80, 81 We have shown the presence of concordant mutations involving EGFR and K-ras in a subgroup of adenocarcinoma and concomitant AAH lesions. This finding further supports the role of these genes in the early stage of pathogenesis of lung adenocarcinoma and suggests that AAH may be a precursor lesion of lung adenocarcinoma. Lack of HER2 mutations is consistent with the involvement of this gene in a limited number of NSCLCs. The finding of different mutations in multiple tumors reinforces the idea that it is crucial to study each independently occurring lung tumor and to start TKI when neoplastic molecular characteristics may predict drug sensitivity; the preliminary comparable clinical results between chemotherapy and EGFR inhibitors in advanced NSCLC also reinforce use of these measures. 82, 83 From the Sections of 1 
